152 related articles for article (PubMed ID: 32440157)
1. Clinicopathological, Immunohistochemical and Molecular Genetic Study on Epithelioid Glioblastoma: A Series of Fifteen Cases with Literature Review.
Zeng Y; Zhu X; Wang Y; Liu B; Yang X; Wang Q; Du J; Ma Y; Lin L; Fu P; Xiao H; Guo QN
Onco Targets Ther; 2020; 13():3943-3952. PubMed ID: 32440157
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features and prognosis of epithelioid glioblastoma.
Wang S; He Q; Zhang Q; Guan B; Zhou X
Int J Clin Exp Pathol; 2020; 13(7):1529-1539. PubMed ID: 32782671
[TBL] [Abstract][Full Text] [Related]
3. [Epithelioid glioblastoma with BRAF V600E mutation: a clinicopathological and molecular study].
Zheng LM; Gong J; Zou Y; Zhang MN; Yu TP; Hou J; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):229-235. PubMed ID: 33677887
[No Abstract] [Full Text] [Related]
4. Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature.
Khanna G; Pathak P; Suri V; Sharma MC; Chaturvedi S; Ahuja A; Bhardwaj M; Garg A; Sarkar C; Sharma R
Pathol Res Pract; 2018 May; 214(5):679-685. PubMed ID: 29615337
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E, TERT promoter mutations and CDKN2A/B homozygous deletions are frequent in epithelioid glioblastomas: a histological and molecular analysis focusing on intratumoral heterogeneity.
Nakajima N; Nobusawa S; Nakata S; Nakada M; Yamazaki T; Matsumura N; Harada K; Matsuda H; Funata N; Nagai S; Nakamura H; Sasaki A; Akimoto J; Hirato J; Yokoo H
Brain Pathol; 2018 Sep; 28(5):663-673. PubMed ID: 29105198
[TBL] [Abstract][Full Text] [Related]
6. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Li H; Li J; Cheng G; Zhang J; Li X
Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
[TBL] [Abstract][Full Text] [Related]
7. Analysis of 24 cases of epithelioid glioblastoma: Experience from a tertiary centre of North India.
Chatterjee D; Radotra BD; Aggarwal D; Madan R; Gupta SK
Ann Diagn Pathol; 2021 Feb; 50():151679. PubMed ID: 33341703
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
9. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter.
Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ
J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of EZH2 expression, BRAF V600E mutation, and CDKN2A/B deletions in epithelioid glioblastoma and anaplastic pleomorphic xanthoastrocytoma.
Wang J; Liu Z; Cui Y; Liu Y; Fang J; Xu L; He Y; Du J; Su Y; Zou W; Xu Z; Li G
J Neurooncol; 2019 Aug; 144(1):137-146. PubMed ID: 31214915
[TBL] [Abstract][Full Text] [Related]
11. Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.
Laxton RC; Popov S; Doey L; Jury A; Bhangoo R; Gullan R; Chandler C; Brazil L; Sadler G; Beaney R; Sibtain N; King A; Bodi I; Jones C; Ashkan K; Al-Sarraj S
Neuro Oncol; 2013 Dec; 15(12):1635-43. PubMed ID: 24158110
[TBL] [Abstract][Full Text] [Related]
12. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics and treatment outcomes of epithelioid glioblastoma.
Sun K; Zhou X; Li T; Zuo M; Li J; Liu Y
Neurosurg Rev; 2021 Dec; 44(6):3335-3348. PubMed ID: 33598819
[TBL] [Abstract][Full Text] [Related]
14. Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma.
Sugimoto K; Ideguchi M; Kimura T; Kajiwara K; Imoto H; Sadahiro H; Ishii A; Kawano H; Ikeda E; Suzuki M
Brain Tumor Pathol; 2016 Apr; 33(2):137-46. PubMed ID: 26667174
[TBL] [Abstract][Full Text] [Related]
15. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.
Li S; Yan C; Huang L; Qiu X; Wang Z; Jiang T
Neuro Oncol; 2012 Jan; 14(1):109-16. PubMed ID: 22039037
[TBL] [Abstract][Full Text] [Related]
16. Cerebellar glioblastoma: a clinical series with contemporary molecular analysis.
Hong B; Banan R; Christians A; Nakamura M; Lalk M; Lehmann U; Hartmann C; Krauss JK
Acta Neurochir (Wien); 2018 Nov; 160(11):2237-2248. PubMed ID: 30203362
[TBL] [Abstract][Full Text] [Related]
17. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcome and molecular characterization of pediatric glioblastoma treated with postoperative radiotherapy with concurrent and adjuvant temozolomide: a single institutional study of 66 children.
Jalali R; Rishi A; Goda JS; Sridhar E; Gurav M; Sharma P; Moiyadi A; Shetty P; Gupta T
Neurooncol Pract; 2016 Mar; 3(1):39-47. PubMed ID: 31579520
[TBL] [Abstract][Full Text] [Related]
19. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
[TBL] [Abstract][Full Text] [Related]
20. A case of osteoclast-like giant cell-rich epithelioid glioblastoma with BRAF V600E mutation.
Funata N; Nobusawa S; Yamada R; Shinoura N
Brain Tumor Pathol; 2016 Jan; 33(1):57-62. PubMed ID: 26602910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
